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Abstract
Background: TRIM25 is a novel RNA-binding protein and a member of the Tripartite Motif (TRIM) family of E3 ubiquitin
ligases, which plays a pivotal role in the innate immune response. However, there is scarce knowledge about its RNA-
related roles in cell biology. Furthermore, its RNA-binding domain has not been characterized.
Results: Here, we reveal that the RNA-binding activity of TRIM25 is mediated by its PRY/SPRY domain, which we postulate
to be a novel RNA-binding domain. Using CLIP-seq and SILAC-based co-immunoprecipitation assays, we uncover TRIM25’s
endogenous RNA targets and protein binding partners. We demonstrate that TRIM25 controls the levels of Zinc Finger
Antiviral Protein (ZAP). Finally, we show that the RNA-binding activity of TRIM25 is important for its ubiquitin ligase activity
towards itself (autoubiquitination) and its physiologically relevant target ZAP.
Conclusions: Our results suggest that many other proteins with the PRY/SPRY domain could have yet uncharacterized
RNA-binding potential. Together, our data reveal new insights into the molecular roles and characteristics of RNA-binding
E3 ubiquitin ligases and demonstrate that RNA could be an essential factor in their enzymatic activity.
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Background
More than 300 novel RNA-binding proteins have been
identified in HeLa [1], HEK293 [2], and mouse ES cells
[3]. Furthermore, a recent study identified 393 new
RNA-binding proteins unique to cardiomyocytes [4].
Strikingly, many of these proteins were not previously
known for their RNA-binding properties and do not
contain canonical RNA-binding domains. Intriguingly,
E3 ubiquitin ligases from the Tripartite Motif (TRIM)
family (TRIM25, TRIM56, and TRIM71) are among
these newly identified RNA-binding proteins. TRIM pro-
teins have a characteristic architecture that includes
RING zinc-finger, B-Box, coiled-coil (CC), and variable
C-terminal domains. There are over 80 TRIM proteins
in the human genome, and they have been divided into
11 subfamilies based on their structural composition [5].
The largest subfamily (C-IV) of 33 TRIM proteins is
characterized by the PRY/SPRY domain at the C-
terminal end. Most proteins from the TRIM family are
involved in innate immune responses [6, 7]. For
example, TRIM25 plays a role in the Retinoic Acid-
Inducible Gene 1 (RIG-I)-mediated interferon response
to viral RNAs [5, 8]. RIG-I recognizes viral RNA mole-
cules with a 5′-triphosphate (5′-ppp-RNA) [9] and initi-
ates a downstream signaling cascade that culminates
with the expression of type I interferons (interferon α
and β) [10] and an anti-viral response. TRIM25 mediates
K63-linked ubiquitination of RIG-I, which leads to effi-
cient recruitment of its downstream partners. Such re-
cruitment in turn triggers the interferon response [11].
Recently, TRIM25 was shown to be required for the
antiviral activity of RNA-binding Zinc Finger Antiviral
Protein (ZAP) [12, 13]. However, little is known about
the RNA-mediated roles and characteristics of these
RNA-binding E3 ligases.* Correspondence: gracjan.michlewski@ed.ac.uk1Wellcome Centre for Cell Biology, University of Edinburgh, Michael Swann
Building, Edinburgh EH9 3BF, UK
Full list of author information is available at the end of the article
© Michlewski et al. 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Choudhury et al. BMC Biology  (2017) 15:105 
DOI 10.1186/s12915-017-0444-9
Although TRIM25 has been generally well characterized,
the functional importance of its RNA-binding activity re-
mains unclear. Our recent study provided the first clues,
showing that the binding of TRIM25 to pre-let-7 leads to
its more efficient Lin28a-mediated uridylation [14]. This
finding raised the possibility that RNA processing may be
spatially controlled through post-translational protein mod-
ifications by RNA-binding protein-modifying enzymes such
as TRIM25. Furthermore, TRIM25 could be using RNA as
a scaffold to ubiquitinate its targets. Importantly, the tran-
scriptome and proteome-wide targets of TRIM25 have not
yet been identified. Finally, its RNA-binding domain has
not been unequivocally described.
Herein, using data from a proteome-wide analysis of
RNA-binding domains, RNA pull-downs, and an electro-
phoretic mobility shift assay (EMSA), we show that the
PRY/SPRY domain of TRIM25 harbors its RNA-binding
activity. Furthermore, TRIM25 CLIP-seq and quantitative
SILAC-based co-immunoprecipitation assays reveal a com-
prehensive overview of interacting RNAs and proteins,
respectively. Our CLIP-seq data identifies hundreds of cod-
ing and non-coding RNAs bound by TRIM25. We show
that TRIM25 binds a distinct set of RNAs and prefers to
bind GC-rich sequences. We also demonstrate that
TRIM25 associates with many RNA-binding proteins, thus
suggesting it could play a role in regulating RNA metabol-
ism. Crucially, we present evidence that the binding of
TRIM25 to RNA is important for its ubiquitin ligase activ-
ity towards itself (autoubiquitination) and its physiologic-
ally relevant target ZAP. Finally, by showing that the PRY/
SPRY regions of other TRIM proteins rescue TRIM25’s
RNA-binding activity, we propose that TRIM25 represents
a novel group of E3 ligases with RNA-binding activity that
use PRY/SPRY as a novel RNA-binding domain. These
results provide original insights into the RNA-mediated
activities of RNA-binding E3 ubiquitin ligases.
Results
TRIM25 directly interacts with RNA through the PRY/SPRY
domain
TRIM25 is known to associate with RNAs in cells and
cell extracts [3, 14]. However, whether this interaction is
direct or indirect remains unknown. To test this, we
performed an EMSA with pre-let-7a-1 and purified
recombinant human His-tagged TRIM25, expressed in
E. coli (Additional file 1: Figure S1a). EMSA, with
increasing amounts of His-TRIM25, revealed that
TRIM25 interacts with RNA directly (Fig. 1a), with an
observed Kd of 800 nM. This showed that TRIM25 was
a bona fide RNA-binding protein.
TRIM25 has been previously shown to bind RNA
through its coiled-coil CC domain [3], which is respon-
sible for its dimerization and oligomerization [15–18].
Surprisingly, a proteome-wide analysis of RNA-binding
domains (RBDs) in HeLa cells revealed that the TRIM25
PRY/SPRY domain may be responsible for direct binding
to RNA (Fig. 1b) [19]. In brief, this method combines
UV protein-RNA crosslinking, oligo(dT) capture, and
controlled proteolysis for a high-resolution (~17 amino
acids on average) delineation of the protein region
engaged in RNA binding, which in the case of TRIM25,
is the peptide enriched in the RNA-bound fraction
mapped to the PRY/SPRY domain (TRIM25 residues
470–508), demonstrating direct RNA binding (red line;
1% false discovery rate, Fig. 1b). In contrast, peptides
mapping to other regions of the protein, including the
CC domain, were released into the supernatant following
protease cleavage (blue lines), suggesting a lack of RNA-
binding activity (Fig. 1b). To validate this, we expressed
and purified a recombinant His-TRIM25 deletion mu-
tant (lacking residues 470–508 located in the PRY/SPRY
domain) (Additional file 1: Figure S1a), which we tenta-
tively named TRIM25ΔRBD, and tested its binding activ-
ity in vitro (Fig. 1c, d). EMSA analysis with increasing
amounts of His-TRIM25ΔRBD revealed no shift in the
pre-let-7a-1 substrate (Fig. 1c). Likewise, RNA pull-
down assays in HeLa cell extracts showed that endogen-
ous and T7-tagged TRIM25 were efficiently pulled-down
with pre-let-7a-1, whereas T7-tagged TRIM25ΔRBD was
not (Fig. 1e). These results strongly indicate that the
TRIM25 PRY/SPRY domain harbors its RNA-binding
activity.
Importantly, some RNA-binding proteins must
dimerize to be able to bind RNA [20, 21]. Since
TRIM25 is known to dimerize and tetramerize through
its CC domain with minimal contributions from the
PRY/SPRY [15–18], we decided to generate TRIM25
knockout (KO) cells, which removed any confounding
effects of endogenous TRIM25. To obtain TRIM25 KO
cells, we used CRISPR/Cas9 targeting followed by
clonal selection and dot blot analysis. This strategy
yielded several HeLa cell clones with complete loss of
TRIM25 expression (Additional file 1: Figure S2a). For
further analysis, we selected clone C3 (Additional file
1: Figure S2b). Next, we performed RNA pull-down as-
says in extracts from the TRIM25 KO cells with T7-
TRIM25ΔRBD and additional TRIM25 truncations
(Fig. 1d). These experiments confirmed that neither
T7-TRIM25ΔRBD nor T7-TRIM25ΔCC retained RNA-
binding activity (Fig. 1f ). Importantly, neither T7-
TRIM25ΔPRY/SPRY nor T7-TRIM25-PRY/SPRY could
bind RNA (Fig. 1g), indicating that the TRIM25 CC
domain is essential, whereas the isolated PRY/SPRY
domain is not sufficient for binding to RNA. These re-
sults suggest that TRIM25 binding to RNA could be
dependent on its CC-mediated dimerization and are in
line with previous results, which linked the CC domain
with TRIM25’s RNA-binding activity [3].
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Finally, we wanted to check if TRIM25ΔRBD could fold
correctly and form multimeric complexes. To test this, we
overexpressed T7-tagged TRIM25 with EGFP-tagged
TRIM25 (with or without the ΔRBD mutation) in TRIM25
KO cells and performed anti-T7 co-immunoprecipitation
(co-IP) assays (Fig. 2a). Our results showed that both wild-
type T7-TRIM25 and T7-TRIM25ΔRBD could interact
with EGFP-TRIM25 (Fig. 2a). The control experiment
revealed that the T7 antibody led to co-IP of T7-tagged but
not EGFP-tagged TRIM25 (Fig. 2b). Moreover, we con-
firmed that T7-TRIM25ΔCC or the isolated T7-TRIM25-
PRY/SPRY domain could not form multimeric complexes
with EGFP-TRIM25 (Fig. 2c). Importantly, both the wild-
type and TRIM25ΔRBD recombinant proteins displayed a
similar melting temperature (43 °C) in a thermal denatur-
ation assay (Additional file 1: Figure S1b). Furthermore,
using size exclusion chromatography with multi-angle light
scattering (MALS), we established that there was no differ-
ence in the elution profiles between the wild-type and the
mutant protein (Additional file 1: Figure S1c). The MALS-
measured mass distribution for His-TRIM25 was 263 ±
5.3 kDa, with an Mw/Mn of approximately 1.01. The His-
TRIM25ΔRBD had values of 258 ± 5 kDa, and ≥ 1.003 Mw/
Mn. This suggests that both wild-type and TRIM25ΔRBD
formed tetramers in our preparation. Taken together, these
results show that TRIM25 harboring a ΔRBD mutation still
supports interactions in trans with another TRIM25 mol-
ecule and that the ΔRBD mutation does not influence the
overall folding or multimerization of the TRIM25 protein.
TRIM25 co-immunoprecipitates with proteins involved in
RNA metabolism
To find TRIM25-interacting proteins, we performed co-
IPs of T7-tagged TRIM25 in HeLa cells coupled with
quantitative SILAC mass spectrometry. In brief, wild-
type T7-tagged TRIM25 was expressed in HeLa cells,
and the co-IP was performed using protein A agarose
beads coupled with the anti-T7 antibody (Fig. 3a). The
control cells (without T7-TRIM25) were grown in
‘heavy’ medium, and the cells expressing T7-tagged
TRIM25 were grown in ‘light’ SILAC medium. This set-
up allowed for a quantitative assessment of proteins that
bound specifically to TRIM25. After the mass spectrom-
etry analysis, the most enriched protein in the co-IP of
T7-TRIM25-expressing cells was TRIM25, which vali-
dated our approach (Additional file 2: Table S1). Next,
we performed functional Gene Ontology-term annota-
tions for enriched proteins using DAVID [22] and visual-
ized the results in Cytoscape with the Enrichment Map
Plugin [23]. Importantly, we found many proteins in-
volved in RNA metabolism such as helicases, RNA
processing, nucleotide binding, ribosomal proteins, or
proteins involved in RNA stability (Fig. 3a). Recently, a
large-scale protein–protein interactome analysis
revealed that RNA-binding proteins are likely to co-
immunoprecipitate higher numbers of other RNA-
binding proteins [24]. Thus, our results emphasize the
role of TRIM25 as an RNA-binding protein.
Next, to see which of these protein–protein interac-
tions are mediated by RNA, we performed the same co-
IP assays using T7-tagged TRIM25ΔRBD (Fig. 3b) or
T7-tagged TRIM25 but in the presence of RNases
(Fig. 3c). In total, 109 proteins were absent in either the
T7-TRIM25ΔRBD or RNase-treated T7-TRIM25 co-IPs
when compared with the wild-type T7-TRIM25 co-IP
(Fig. 3d). These proteins, which most likely interact with
TRIM25 through RNA, are associated with RNA pro-
cessing and splicing, RNA stability, RNA transport, and
helicase activity. We have validated that a recently iden-
tified, physiologically relevant TRIM25 ubiquitination
substrate – RNA-binding ZAP [12, 13] – interacts with
T7-TRIM25 but not T7-TRIM25ΔRBD (Fig. 3e). ZAP
has longer and shorter isoforms, which differ by the
presence or absence of the poly(ADP-ribose) polymerase
domain in the C-terminal region. The binding of both
isoforms to TRIM25 was severely reduced upon RNase
treatment, proving that the interaction is dependent on
the RNA (Fig. 3e). Likewise, DDX5 was predominantly
(See figure on previous page.)
Fig. 1 TRIM25 is a bona fide RNA-binding protein and the PRY/SPRY domain is responsible for binding to RNA. a EMSA analysis of recombinant
His-tagged TRIM25 with pre-let-7a-1. Lane 1 represents the loading control. Lanes 2–11 show EMSA with increasing amounts of TRIM25 (200, 400,
600, 800, 1000, 1200, 1400, 1600, 1800, and 2000 ng). b RNA capture assay result for TRIM25. Red line represents peptide enriched in the RNA-
bound fraction. Blue lines show peptides depleted from the RNA-bound fraction. c EMSA analysis of recombinant His-tagged TRIM25ΔRBD with
pre-let-7a-1. Lane 1 represents the loading control. Lanes 2–11 show EMSA with increasing amounts of TRIM25ΔRBD (200, 400, 600, 800, 1000,
1200, 1400, 1600, 1800, and 2000 ng). d Domain architecture of wild-type TRIM25 and deletion mutants. Relative position of RNA-enriched peptide is
shown in red. e Western blot analyses against T7, TRIM25, and DHX9 of pre-let-7a-1 pull-downs with HeLa cell extracts overexpressing T7-TRIM25 or T7-
TRIM25ΔRBD. Lanes 1, 4, and 7 represent 4% (40 μg) of the loading controls (input). Lanes 2, 5, and 8 represent bead-only pull-downs. Lanes 3, 6, and 9
show pre-let-7a-1 pull-down. Note that T7 antibody highlights an unspecific band visible in lanes 3 and 8. f Western blot analyses against T7 and DHX9
of pre-let-7a-1 pull-downs with HeLa TRIM25 KO cell extracts overexpressing T7-TRIM25, T7-TRIM25ΔRBD, or T7-TRIM25ΔCC. Lanes 1, 4, and 7 represent
4% (40 μg) of the loading controls (input). Lanes 2, 5, and 8 represent bead-only pull-downs. Lanes 3, 6, and 9 show pre-let-7a-1 pull-down. g Western
blot analyses against T7 and DHX9 of pre-let-7a-1 pull-downs with HeLa TRIM25 KO cell extracts overexpressing T7-TRIM25ΔPRY/SPRY or T7-TRIM25-
PRY/SPR. Lanes 1 and 4 represent 4% (40 μg) of the loading controls (input). Lanes 2 and 5 represent bead-only controls. Lanes 3 and 6 show
pre-let-7a-1 pull-down
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detected in the co-IP with T7-TRIM25 but not with T7-
TRIM25ΔRBD, although the RNase treatment resulted
in only a decreased interaction (Fig. 3e). Importantly,
many proteins that were enriched in the T7-
TRIM25ΔRBD and RNase-treated T7-TRIM25 assays
were associated with ribosomal and translation functions
(Fig. 3b, c), representing RNA-independent interactions
with TRIM25 (Additional file 2: Table S1). Surprisingly,
the T7-TRIM25ΔRBD and RNase-treated T7-TRIM25
co-IPs detected several proteins that were not seen in
the wild-type T7-TRIM25 co-IP, likely due to a synthetic
effect of the mutation, lack of binding to RNA, or
Fig. 2 T7-TRIM25ΔRBD supports TRIM25 dimerization. a Co-immunoprecipitation (co-IP) between T7-tagged TRIM25 and EGFP-tagged TRIM25 in
cell extracts prepared from HeLa TRIM25 KO cells overexpressing wild-type or ΔRBD TRIM25 mutants. Lanes 1–4 represent loading controls. Lanes
5–8 show co-IPs with anti-T7 antibody. Lanes 9–12 represent control co-IPs with IgG antibody bound to protein-A beads. The bound proteins were
analyzed by western blotting with anti-TRIM25 antibody. b Control co-IP shows that co-IP of EGFP-TRIM25 and EGFP-TRIM25 did not occur with anti-T7
antibody. Lanes 1–4 represent loading controls. Lanes 5–8 show co-IPs with anti-T7 antibody. Lanes 9–12 represent control co-IPs with IgG antibody
bound to protein-A beads. The bound proteins were analyzed by western blotting with anti-TRIM25 antibody. c Control co-IP in HeLa TRIM25 KO cell
extracts reveals that T7-TRIM25ΔRBD and T7-TRIM25ΔPRY/SPRY, but not T7-TRIM25ΔCC or T7-TRIM25-PRY/SPRY, support dimerization. Lanes 1–4 represent
loading controls. Lanes 5–8 show co-IPs with anti-T7 antibody. Lanes 9–12 represent control co-IPs with IgG antibody bound to protein-A beads. The
bound proteins were analyzed by western blotting with anti-TRIM25 and anti-T7 antibodies
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Fig. 3 SILAC combined with TRIM25 co-immunoprecipitation (co-IP) reveals a network of associated RNA-binding proteins. a A diagram of a co-IP
experiment with T7-tagged TRIM25 in the presence of endogenous RNAs together with Gene Ontology enrichment map of proteins co-
immunoprecipitated with T7-TRIM25. Enriched protein sets are represented as nodes (red circles) connected by edges (green lines), with the size of nodes
and edges representing the number of proteins in gene sets and amount of overlap. b A diagram of a co-IP experiment with T7-tagged TRIM25ΔRBD in
the presence of endogenous RNAs accompanied by the Gene Ontology enrichment map of proteins co-immunoprecipitated with T7-TRIM25ΔRBD. c A
diagram of a co-IP experiment with T7-tagged TRIM25 in the presence of RNases together with Gene Ontology enrichment map of
proteins co-immunoprecipitated with T7-TRIM25 in the presence of RNases. d Venn diagram representing numbers of overlapping proteins
identified in the co-IPs with T7-TRIM25, T7-TRIM25ΔRBD, and T7-TRIM25 in the presence of RNases. e Validation of co-IP experiments show
western blot against ZAP and DDX5 proteins. ZAP has two isoforms co-immunoprecipitated by T7-TRIM25 but not by T7-TRIM25ΔRBD or
T7-TRIM25 in the presence of RNases. Note that anti-ZAP antibody is picking up a signal from overexpressed TRIM25. DDX5 binding to
TRIM25 is partially RNA-dependent as co-IP by T7-TRIM25 in the presence of RNases decreases but does not eliminate its interaction with
TRIM25. Lanes 1–3 represent loading controls. Lane 4 shows control co-IPs in mock HeLa cell extracts. Lanes 5–7 show anti-T7 co-IP.
f Western blot analysis of wild-type (WT) and TRIM25 knock-out (KO) HeLa cells shows upregulation of ZAP protein in the KO cells. DDX5
levels do not change and serve as a loading control
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unspecific binding events. Altogether, these results re-
affirm that the PRY/SPRY domain is important for
RNA-binding and show that TRIM25 interacts with
many RNA-binding proteins, using RNA as a scaffold.
We set out to find out if TRIM25 KO results in glo-
bal perturbation of protein levels. To do so, we used
SILAC mass spectrometry on the wild-type and
TRIM25 KO HeLa cells. Our results showed that the
levels of only a few proteins were affected more than
two-fold (Additional file 3: Table S2). Among the
affected proteins we found ZAP, which was substan-
tially upregulated in TRIM25 KO cells when compared
with the wild-type cells. Western blot analysis of the
wild-type and KO cells validated this observation
(Fig. 3f ). To see if TRIM25-dependent proteasome deg-
radation of ZAP contributes to its lower levels in the
wild-type cells we treated the cells with proteasome
inhibitor MG132. Upon MG132 treatment, we noticed
an increase in ZAP levels only in the wild-type cells but
not in the TRIM25 KO cells (Additional file 1: Figure
S2c). Conversely, the signal corresponding to ubiquitin
was elevated in both wild-type and TRIM25 KO cells
(Additional file 1: Figure S2d). Importantly, overexpres-
sion of T7-TRIM25, but not of T7-TRIM25ΔRBD or
catalytically inactive T7-TRIM25ΔRING, decreased the
levels of ZAP in TRIM25 KO cells (Additional file 1:
Figure S2e), demonstrating that TRIM25-mediated pro-
teasome degradation of ZAP contributes to its normal
levels. Furthermore, these results suggest that the func-
tional interaction between TRIM25 and ZAP is RNA
dependent.
CLIP-seq reveals an extensive TRIM25 RNA interactome
To detect endogenous RNA substrates of TRIM25, we
performed UV crosslinking and immunoprecipitations in
HeLa cells transiently expressing T7-tagged TRIM25,
followed by high-throughput sequencing of TRIM25-
associated RNAs (CLIP-seq). After UV crosslinking and
immunoprecipitation, we observed a specific RNA-
protein complex (Additional file 1: Figure S3a). CLIP-seq
of T7-TRIM25ΔRBD resulted in a lack of detectable
RNA-protein interactions (data not shown). The RNA
from the T7-TRIM25/RNA complex was isolated using a
CLIP-seq protocol and sequenced on a HiSeq platform.
Data analysis and cluster identification using pyCRAC
[25] revealed a significant correlation between three bio-
logical replicates, with a correlation coefficient between
clusters from 0.94 to 0.96 (Additional file 1: Figure S4).
A total of 5549 clusters were common between all three
experiments, and we identified 2611 distinct transcripts
(Additional file 4: Table S3). Importantly, there was no
correlation between transcript abundance, measured by
a separate RNA-seq assay, and the cluster intensities,
with a Pearson correlation of 0.1 (Additional file 1:
Figure S5), showing that TRIM25 does not simply bind
the most abundant RNAs but has a substrate preference.
Among the identified transcripts, mRNAs and lincR-
NAs were the most abundant (Fig. 4a). Gene Ontology-
term annotation of TRIM25-bound transcripts revealed
several nodes, including RNA processing and transla-
tion, WD repeats, phosphorylation, and ubiquitination
(Additional file 1: Figure S6a).
To determine the TRIM25 binding sequence prefer-
ence, we used the pyMotif program from the pyCRAC
package and WebLogo on identified clusters to search
for enriched k-mers. While no single strong consensus
motif was identified, we found that TRIM25 prefers G-
and C-rich sequences (Fig. 4b). This was confirmed by a
bioinformatics analysis showing a significantly higher
GC content in TRIM25 clusters compared to random
transcripts or random exons (P values for both compari-
sons were 2.2 × 10–16) (Fig. 4c). When we clustered our
consensus motifs we found some discrete, G- and C-rich
short motifs (Additional file 1: Figure S6b). In the future,
it will be interesting to check if any of these motifs con-
tribute towards TRIM25’s RNA-binding specificity. Next,
we assessed the distribution of TRIM25 binding in
mRNAs. This revealed that most binding sites are in
exons (56%), with the 3′-UTR also prominently repre-
sented (23%) (Fig. 4d). Furthermore, we observed a no-
ticeable enrichment of TRIM25 clusters just after the
stop codon (Fig. 4e). TRIM25 binds to its own tran-
script, which could be biologically important (Additional
file 1: Figure S3b). Intriguingly, even though TRIM25 is
localized to both nucleus and cytoplasm [14], intron
binding events were not common in CLIP-seq analysis;
this could be demonstrated on TRIM25 mRNA target c-
Myc. Both high throughput CLIP-seq and TRIM25 RNA
immunoprecipitation (RIP) followed by targeted amplifi-
cation of c-Myc transcript showed that TRIM25 pre-
dominantly interacts with mature mRNA (Additional file
1: Figure S3c, d). Nevertheless, TRIM25 interacts with
many RNA-binding proteins (Fig. 3) and they could pro-
vide a platform for interactions with other targets at the
level of pre-mRNAs.
To validate the CLIP-seq experiments, we performed
RIP followed by qRT-PCR of selected TRIM25 targets in
HeLa cells overexpressing either wild-type T7-TRIM25
or T7-TRIM25ΔRBD (Fig. 4f, g). RIP qRT-PCR with the
wild-type TRIM25 showed significant enrichment of
tested mRNAs (Fig. 4f ) and miRNAs (Fig. 4g). Intri-
guingly, the T7-TRIM25 RIP signal on TRIM25 mRNA
was much higher than that on other substrates (Fig. 4f ).
This could not be explained by increased levels of
TRIM25 mRNA, which was upregulated only three-fold
when compared to the mock-transfected control (data
not shown). Importantly, T7-TRIM25ΔRBD failed to
precipitate any RNAs apart from TRIM25 mRNA itself
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(Fig. 4f ). These results could be explained by the binding
of the T7 antibody to the nascent TRIM25, which was
still associated with polyribosomes and TRIM25 mRNA.
As the T7 antibody could co-IP many nascent TRIM25
peptides, which were still associated with the TRIM25
mRNA, the RIP signal would be increased. Altogether,
these results uncover the first TRIM25/RNA interac-
tome, suggesting that TRIM25 RNA-related functions
may extend well beyond the regulation of pre-let-7 uri-
dylation toward other aspects of RNA metabolism. Fi-
nally, these data clearly demonstrate that one of the
main TRIM25 targets is its own mRNA.
To gain further insights into TRIM25’s role in RNA
metabolism we have used qRT-PCR to analyze mRNA
levels of selected targets (the same ones as assayed by
RIP in Fig. 4f, g) and ZAP mRNA in the wild-type and
TRIM25 KO cells. The majority of analyzed transcripts
did not display substantial difference between wild-type
and KO cells (Additional file 1: Figure S7a, b). ZAP and
RNU12 transcripts were moderately upregulated in the
TRIM25 KO cells when compared with the wild-type
ones. To see if TRIM25 could regulate stability of tran-
scripts we blocked pol II transcription by Actinomycin
D and assayed the levels of selected RNAs by qRT-PCR
at various time points (Additional file 1: Figure S7c–e).
No statistically significant difference between wild-type
and the TRIM25 KO cells was observed in the stability
of ZAP and c-Myc transcripts (Additional file 1: Figure
S7c–e), suggesting that the steady-state ZAP mRNA
level change seen in the TRIM25 KO cells is due to tran-
scriptional control; this is not surprising as a recent
study revealed that TRIM25 is a potent transcriptional
regulator [26]. Further in-depth and high throughput
experiments will be needed to fully understand the po-
tential role of TRIM25 in RNA metabolism.
Binding of TRIM25 to its mRNA augments TRIM25
ubiquitination
To uncover the RNA-related function of TRIM25 and
the reason behind its binding to its own mRNA, we
focused on the well-documented molecular event of
TRIM25 K117 autoubiquitination [27]. We confirmed
that TRIM25 undergoes autoubiquitination by co-
overexpression and co-IP of T7-tagged TRIM25 to-
gether with HA-tagged ubiquitin (Additional file 1: Figure
S8a, b). This was also confirmed by the in vitro ubiquitina-
tion experiments described below. Next, we asked if bind-
ing of TRIM25 to its own mRNA augmented TRIM25
ubiquitination. To address this, we overexpressed EGFP-
TRIM25 or EGFP-TRIM25ΔRBD in HeLa cells and
assayed for TRIM25 ubiquitination. We used EGFP fusion
proteins to distinguish overexpressed and endogenous
TRIM25. The overexpression of EGFP-TRIM25 led to the
appearance of modified EGFP-TRIM25 (Fig. 5a, b). How-
ever, upon EGFP-TRIM25ΔRBD overexpression, the inten-
sity of the modified band was noticeably reduced (Fig. 5a,
b). Of note, we had to use more EGFP-TRIM25ΔRBD
plasmid to achieve protein expression comparable to that
of EGFP-TRIM25. Surprisingly, overexpression of EGFP-
TRIM25, but not EGFP-TRIM25ΔRBD, led to significant
accumulation of modified forms of endogenous TRIM25,
with much higher ratios of the modified forms compared
to the non-modified form (Fig. 5a, b). These results sug-
gest that the intact RBD is required for efficient ubiquiti-
nation and show that endogenous TRIM25 can be
modified by EGFP-TRIM25 to a much greater extent than
EGFP-TRIM25 modifies itself. One important difference
between endogenous TRIM25 mRNA and the mRNA
coding for EGFP-TRIM25 is the presence of 5′- and 3′-
UTRs, which were shown to bind TRIM25 in the CLIP-
seq experiments (Additional file 1: Figure S3b).
To determine if the TRIM25 3′-UTR can contribute
to ubiquitination of TRIM25, we used a catalytically
dead T7-TRIM25ΔRING construct, which cannot
undergo autoubiquitination, and transfected it into
TRIM25 KO cells. We also used a T7-
TRIM25ΔRING_3′-UTR construct that contained the
TRIM25 3′-UTR. Notably, we had to use more T7-
TRIM25ΔRING_3′-UTR plasmid to achieve protein
expression comparable to that of T7-TRIM25ΔRING
(Fig. 5c), most likely due to microRNA/3′-UTR-medi-
ated control of protein expression. As predicted, T7-
TRIM25ΔRING does not support efficient autoubiqui-
tination (Fig. 5c). However, upon EGFP-TRIM25 over-
expression, we noticed the appearance of ubiquitinated
forms of T7-TRIM25ΔRING (Fig. 5c, d). We could not
(See figure on previous page.)
Fig. 4 CLIP-seq of T7-TRIM25 in HeLa cells reveals TRIM25’s RNA targets. a The distribution of TRIM25 CLIP-seq clusters in total RNA. b The ab
initio-derived TRIM25-binding sequence preference. T is representative of U in the RNA. c GC content is significantly enriched in TRIM25 CLIP-seq
clusters as compared to randomly selected transcripts or exons with a similar length distribution (transcripts detected in HeLa RNA-seq);
P value 2.2 × 10–16. d The distribution of TRIM25 CLIP-seq clusters in mRNAs. e The distribution of TRIM25 CLIP clusters across the protein
coding genes reveals increased frequency in 5′- and 3′-UTRs. f, g RNA-immunoprecipitation (RIP) validates CLIP-seq data and PRY/SPRY as
the RNA-interacting domain. HeLa cells were mock transfected, transfected with T7-TRIM25 or T7-TRIM25ΔRBD, and the extracts immunoprecipitated
with anti-T7 antibody. f qRT-PCR results from RIP assay for selected protein coding and non-coding RNAs. The values are relative to those obtained
from mock transfected cells, which were set to 1. The mean and standard deviations (SD) of three independent biological replicates are shown.
g qRT-PCR results from RIP assay for selected miRs. The values are relative to those obtained from mock transfected cells, which were set to 1. The mean
and SD of three independent biological replicates are shown
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detect abundant ubiquitination bands in T7-TRIM25Δ
RING when EGFP-TRIM25ΔRBD was co-over
expressed (Fig. 5c, d). Even so, the ratio between the
ubiquitinated and main bands still showed a positive
value, most likely due to weaker expression of T7-
TRIM25ΔRING in the presence of EGFP-TRIM25ΔR
BD and to background noise. Importantly, when we co-
overexpressed the T7-TRIM25ΔRING_3′-UTR con-
struct with EGFP-TRIM25, we observed a noticeable
increase in the ratio of ubiquitinated versus non-
ubiquitinated bands for TRIM25ΔRING, when compared
with the T7-TRIM25ΔRING construct without the 3′-
UTR (Fig. 5c, d). To prove that the observed modification
of TRIM25 was specific to K117 we performed similar
analyses with T7-TRIM25ΔRING_K117R constructs. We
did not observe modification of T7-TRIM25ΔRING_K1
17R in the absence or presence of EGFP-TRIM25
(Additional file 1: Figure S8c). Altogether, these results
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Fig. 5 TRIM25 binding to the RNA augments TRIM25 ubiquitination. a Western blot analysis of HeLa cells transfected with EGFP-TRIM25 or
EGFP-TRIM25ΔRBD. Lane 1 shows mock transfected control. Lanes 2 and 3 represent results of transfection with increasing amounts of plasmid
coding for EGFP-TRIM25 (250 and 500 ng). Lanes 4 and 5 represent results of transfection with increasing amounts of plasmid coding for EGFP-
TRIM25ΔRBD (1000 and 2000 ng). b Quantification of western blot results shown in (a). The values show the ratios between the intensity of modified
versus main bands. The results are derived from three independent biological replicates and the mean and standard deviations are shown. c Western
blot analysis of TRIM25 KO HeLa cells transfected with plasmids coding for T7-TRIM25ΔRING (250 ng) or T7-TRIM25ΔRING_3′-UTR (500 ng) as well as
increasing amounts of plasmids coding for EGFP-TRIM25 or EGFP-TRIM25ΔRBD. Lane 1 shows T7-TRIM25ΔRING control. Lanes 2 and 3 represent results
of transfections with T7-TRIM25ΔRING and increasing amounts of EGFP-TRIM25 (250 and 500 ng). Lanes 4 and 5 show results of transfection with T7-
TRIM25ΔRING and increasing amounts of EGFP-TRIM25ΔRBD (1000 and 2000 ng). Lane 6 shows T7-TRIM25ΔRING_3′-UTR control. Lanes 7 and 8 represent
results of transfections with T7-TRIM25ΔRING_3′-UTR and increasing amounts of EGFP-TRIM25 (250 and 500 ng). Lanes 9 and 10 show results of transfection
with T7-TRIM25ΔRING_3′-UTR and increasing amounts of EGFP-TRIM25ΔRBD (1000 and 2000 ng). d Quantification of western blot results shown in (c). The
values show the ratios between the intensity of modified versus main bands. The results are derived from three independent biological replicates and the
mean and standard deviations are shown
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strongly suggest that RNA elements such as the 3′-
UTR, as well as TRIM25 binding to the RNA, contrib-
ute to TRIM25 ubiquitination.
RNA is necessary for efficient TRIM25 ubiquitination in vitro
To test if RNA is necessary for efficient TRIM25 ligase
activity, we performed in vitro ubiquitination assays
with various TRIM25 constructs (Fig. 6a). Incubation of
T7-TRIM25 or T7-TRIM25ΔRBD immunoprecipitated
from HeLa cells with recombinant proteins from the ubi-
quitin pathway (Ube2D3, UBE1, and Ubiquitin) revealed
efficient, time-dependent ubiquitination of TRIM25
but not TRIM25ΔRBD (Fig. 6b). Residual ubiquitina-
tion of TRIM25ΔRBD could arise from the direct
transfer of ubiquitin from Ube2D3 to the substrate.
Next, to show that the observed ubiquitination was
specific and dependent on the intrinsic activity of
TRIM25, we assayed T7-TRIM25ΔRING and T7-
TRIM25K117R. Neither T7-TRIM25ΔRING nor T7-
TRIM25K117R was efficiently ubiquitinated com-
pared to wild-type T7-TRIM25 (Fig. 6c), confirming
the specificity of the in vitro ubiquitination assay.
Fig. 6 In vitro ubiquitination shows that RNA is important for TRIM25 E3 ubiquitin ligase activity. a Domain architecture of wild-type TRIM25,
TRIM25 deletions mutants, and TRIM25 K117R mutant. b T7-TRIM25, but not T7-TRIM25ΔRDB, is efficiently ubiquitinated in vitro. Ubiquitination
assays were performed on immunoprecipitated T7-TRIM25 or T7-TRIM25ΔRDB from HeLa cell extracts in the presence of recombinant purified
6xHis-Ube2D3, UBE1, and ubiquitin. Lanes 1 and 2 show immunoprecipitated T7-tagged proteins. Lanes 3–5 show incubation of T7-TRIM25
with 6xHis-Ube2D3, UBE1, and ubiquitin for 5, 30, and 60 minutes, respectively. Lane 6 represents 60 minutes’ reaction with T7-TRIM25, UBE1,
and ubiquitin. Lanes 7–9 show incubation of T7-TRIM25ΔRDB with 6xHis-Ube2D3, UBE1, and ubiquitin for 5, 30, and 60 minutes, respectively.
Lane 10 represents 60 minutes’ reaction with T7-TRIM25ΔRDB, UBE1, and ubiquitin. The proteins were analyzed by western blotting with anti-
TRIM25 antibody. c Neither T7-TRIM25ΔRING nor T7-TRIM25K117R are efficiently ubiquitinated in vitro. Ubiquitination assays preformed on
immunoprecipitated T7-TRIM25, T7-TRIM25ΔRING, or T7-TRIM25K117R from HeLa cell extracts in the presence of recombinant purified 6xHis-
Ube2D3, UBE1, and ubiquitin. Lanes 1–3 show immunoprecipitated T7-tagged proteins. Lanes 4, 6, and 8 represent 60 minutes’ reaction with
T7-tagged immunoprecipitated proteins, 6xHis-Ube2D3, UBE1, and ubiquitin. Lanes 5, 7, and 9 represent 60 minutes’ reaction with T7-tagged
immunoprecipitated proteins, UBE1, and ubiquitin. The proteins were analyzed by western blotting with anti-TRIM25 antibody. d RNase A/T1
treatment significantly reduces efficiency of T7-TRIM25 ubiquitination. Lane 1 shows immunoprecipitated T7-TRIM25. Lanes 2 and 3 represent
the control 60 minutes’ incubation of HeLa cell extracts in the absence and presence of RNases, respectively. Lanes 4 and 7 show reactions
with immunoprecipitated T7-TRIM25, 6xHis-Ube2D3, UBE1, and ubiquitin in the absence and presence of RNases, respectively. Lanes 5 and 8
show reactions with immunoprecipitated T7-TRIM25, UBE1, and ubiquitin in the absence and presence of RNases, respectively. Lanes 6 and 9
show reactions with immunoprecipitated T7-TRIM25 in the absence and presence of RNases, respectively. The proteins were analyzed by
western blotting with anti-TRIM25 antibody
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Finally, to see if TRIM25 ubiquitin-ligase activity
was dependent on RNA, we performed the ubiquiti-
nation assay in the absence or presence of RNase A/
T1. Remarkably, treatment with RNase A/T1 severely
inhibited in vitro ubiquitination of T7-TRIM25
(Fig. 6d). Interestingly, RNase A/T1-treated reactions
still supported TRIM25 monoubiquitination, likely
due to the direct transfer of ubiquitin from Ube2D3
to TRIM25. These results strongly indicate that RNA
constitutes an important component of the TRIM25
ubiquitin ligase activity.
Homologous sequences from TRIM proteins rescue the
TRIM25 RNA-binding and ubiquitination activities
To further verify our findings and test whether other
TRIM proteins with PRY/SPRY domains could have
RNA-binding potential, we prepared constructs encoding
chimeric proteins, where the TRIM25 RBD was
substituted with homologous sequences from several
TRIM proteins (TRIM5, TRIM21, TRIM27, and TRIM65)
(Fig. 7a). Moreover, we designed a TRIM25 construct with
a scrambled amino acid sequence of the TRIM25 RBD
(Fig. 7a). The chimeric TRIM25 protein constructs
expressed in HeLa cells showed various levels of modifica-
tion (Fig. 7b). Importantly, neither T7-TRIM25ΔRBD nor
T7-TRIM25RBD_src was ubiquitinated (Fig. 7b). To see if
these results translated to RNA-binding efficiency, we per-
formed RNA pull-down assays with pre-let-7a-1 in HeLa
cell extracts. Control assays confirmed that T7-TRIM25,
but not T7-TRIM25ΔRBD, could bind RNA (Fig. 7c). All
chimeric TRIM25 proteins, apart from T7-TRIM25
ΔRBD_src, showed efficient binding to RNA (Fig. 7d, e).
Notably, we did not observe modified bands for TRIM25
in the RNA pull-down assays because the total protein
amounts loaded on the gel were one order of magnitude
lower than those in the overexpression experiments. To
our surprise, there was a strong positive correlation
(correlation coefficient 0.87, P = 0.01) between protein
modification and RNA pull-down efficiencies (Fig. 7f).
Altogether, these results imply that RNA-binding is an im-
portant element in TRIM25 ubiquitination efficiency and
suggest that many other TRIM proteins with the PRY/
SPRY domain could harbor, as yet uncharacterized, RNA-
binding potential.
RNA is necessary for efficient ubiquitination of ZAP by
TRIM25 in vitro
To test if RNA was necessary for efficient ubiquitination
of ZAP, a physiologically important TRIM25 target, we
performed in vitro ubiquitination assays of ZAP (ZAP
short) with the TRIM25 constructs described earlier
(Fig. 6a). Incubation of T7-ZAP with T7-TRIM25 or T7-
TRIM25ΔRBD immunoprecipitated from HeLa cells
with recombinant proteins from the ubiquitin pathway
revealed efficient time-dependent ubiquitination of ZAP
by TRIM25 but not TRIM25ΔRBD (Fig. 8b). Notably, to
see efficient ubiquitination of ZAP we had to use higher
concentrations of recombinant proteins from the
ubiquitin pathway than those used for TRIM25 autoubi-
quitination experiments. As a result, TRIM25 autoubi-
quitination was much more pronounced in experiments
with ZAP (Fig. 8a) than seen in the case of TRIM25-
only assays (Fig. 6b). Furthermore, it has been recently
reported that ZAP enhances TRIM25 autoubiquitination
[13]. Next, to show that the observed ZAP ubiquitina-
tion was specific and dependent on the activity of TRIM
25, we assayed T7-TRIM25ΔRING and T7-TRIM25K
117R. TRIM25ΔRING but not T7-TRIM25K117R lost
the ability to ubiquitinate T7-ZAP (Fig. 8b). Intriguingly,
we observed autoubiquitination of T7-TRIM25K117R,
which could be explained by increased concentrations of
the proteins from the ubiquitination pathway and ZAP
stimulatory activity towards TRIM25 [13]. Finally, to see
if TRIM25 E3 ubiquitin ligase activity towards ZAP was
dependent on RNA, we performed the ubiquitination
assay in the absence or presence of RNase A/T1. Im-
portantly, the treatment with RNase A/T1 severely
inhibited in vitro T7-ZAP ubiquitination by T7-TRIM25
(Fig. 8c). These results strongly indicate that TRIM25
uses RNA as a scaffold for efficient ubiquitination of its
protein targets.
Discussion
TRIM25 E3 ubiquitin ligase is a new RNA-binding
protein with a role in Lin28a-mediated uridylation of
pre-let-7 transcripts [14]. Here, we revealed that the
RNA-binding activity of TRIM25 is contained in its
PRY/SPRY region. We also presented the first high-
throughput analysis of the molecular interactomes of
TRIM25. We showed that TRIM25 is a bona fide RNA-
binding protein associated with many proteins involved
in RNA metabolism and that interacts with numerous
coding and non-coding transcripts. This suggests that
TRIM25 could play a role in the regulation of RNA me-
tabolism. Our data showed that TRIM25 binding to
RNA, and to the 3′-UTR of TRIM25 mRNA in particu-
lar, can augment its autoubiquitination. Finally, we dem-
onstrated that RNA is an important constituent of
TRIM25’s ubiquitin ligase activity towards itself and its
physiologically relevant protein target ZAP. Recently,
ZAP was shown to suppress HIV-1 replication by bind-
ing CG-rich regions in viral RNAs [28]. Intriguingly, the
first paper that described ubiquitin conjugation to sub-
strates showed that tRNA is required for selected ubi-
quitination reactions [29]. We propose a model whereby
the ubiquitin ligase activity of TRIM25 is substantially
enhanced by using RNA as a scaffold (Fig. 9a). Alterna-
tively, binding of TRIM25 to RNA could enhance its
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ubiquitin ligase activity by allosteric changes (Fig. 9b).
These models should be verified by detailed structural
analysis of the free and RNA-bound TRIM25. Finally, it
is exciting to speculate that activity of many other E3
ubiquitin ligases could depend on binding to RNA.
Our results carry very important functional implica-
tions given that the 3′-UTRs are platforms for regula-
tory RNA-binding proteins and that the lengths of the
3′-UTRs associated with specific mRNAs are variable.
For example, cancer cells have mRNAs with much
Fig. 7 Chimeric TRIM25 proteins display correlated RNA-binding and ubiquitination activities. a Domain architecture of wild-type TRIM25 with
indicated RBD and chimeric homologous sequences introduced from other TRIM proteins as well as scrambled TRIM25 RBD sequence (aligned
with Clustal Omega). b Western blot analysis of T7-TRIM25 chimeric proteins. Lanes 1 and 7 show blot of mock transfected HeLa cells. Lanes 2–6, 8,
and 9 represent western blot analysis of overexpressed T7-TRIM25, T7-TRIM25/5, T7-TRIM25/21, T7-TRIM25/27, T7-TRIM25ΔRDB, T7-TRIM25RBD_scr, and
T7-TRIM25/65, respectively. c Western blot analyses against T7 and DHX9 of pre-let-7a-1 pull-downs with HeLa cell extracts overexpressing T7-TRIM25
or T7-TRIM25ΔRBD. Lanes 1, 4, and 7 represent 4% (40 μg) of the loading controls (input). Lanes 2, 5, and 8 represent bead-only pull-downs. Lanes 3, 6,
and 9 show pre-let-7a-1 pull-down. Note that the T7 antibody highlights an unspecific band visible in lanes 3 and 8. d Western blot analyses against
T7 and DHX9 of pre-let-7a-1 pull-downs with HeLa cell extracts overexpressing T7-TRIM25/5, T7-TRIM25/21, or T7-TRIM25/27. Lanes 1, 4, and 7 represent
4% (40 μg) of the loading controls (input). Lanes 2, 5, and 8 represent bead-only pull-downs. Lanes 3, 6, and 9 show pre-let-7a-1 pull-down. e Western
blot analyses against T7 and DHX9 of pre-let-7a-1 pull-downs with HeLa cell extracts overexpressing T7-TRIM25RBD_scr or T7-TRIM25/65. Lanes 1, 4,
and 7 represent 4% (40 μg) of the loading controls (input). Lanes 2, 5, and 8 represent bead-only pull-downs. Lanes 3, 6, and 9 show pre-let-7a-1
pull-down. Note that the T7 antibody highlights an unspecific band visible in lanes 3 and 6. f Graph displaying a positive person correlation coefficient
(0.87) between TRIM25 ubiquitination efficiency (obtained by dividing signal intensities of modified protein bands by main protein bands (b)) and
pull-down efficiency (obtained by dividing signal intensities of pull-down band to input (c, d, e))
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Fig. 8 RNA is a scaffold for TRIM25-mediated ubiquitination of ZAP. a T7-TRIM25 but not T7-TRIM25ΔRDB efficiently ubiquitinated T7-ZAP protein
in vitro. Ubiquitination assays were performed on immunoprecipitated T7-ZAP with T7-TRIM25 or T7-TRIM25ΔRDB from HeLa cell extracts in the
presence of recombinant purified 6xHis-Ube2D3, UBE1, and ubiquitin (the concentrations of proteins from the ubiquitin pathway was higher (hc) than
in the experiments presented in Fig. 6). Lanes 1 and 2 show immunoprecipitated T7-tagged proteins. Lanes 3–5 show incubation of T7-TRIM25 and
T7-ZAP with 6xHis-Ube2D3, UBE1, and ubiquitin for 5, 30, and 60 minutes, respectively. Lane 6 represents 60 minutes’ reaction with T7-TRIM25, T7-ZAP,
UBE1, and ubiquitin. Lanes 7–9 show incubation of T7-TRIM25ΔRDB and T7-ZAP with 6xHis-Ube2D3, UBE1, and ubiquitin for 5, 30, and 60 minutes,
respectively. Lane 10 represents 60 minutes’ reaction with T7-TRIM25ΔRDB, T7-ZAP, UBE1, and ubiquitin. The proteins were analyzed by western
blotting with anti-ZAP and anti-TRIM25 antibodies. b T7-TRIM25ΔRING but not T7-TRIM25K117R are defective in ZAP ubiquitination. Ubiquitination
assays preformed on immunoprecipitated T7-ZAP with T7-TRIM25, T7-TRIM25ΔRING, or T7-TRIM25K117R from HeLa cell extracts in the presence of
recombinant purified 6xHis-Ube2D3, UBE1, and ubiquitin. Lanes 1–3 show immunoprecipitated T7-tagged proteins. Lanes 4, 6, and 8 represent 60 -
minutes’ reaction with T7-tagged immunoprecipitated proteins, 6xHis-Ube2D3, UBE1, and ubiquitin. Lanes 5, 7, and 9 represent 60 minutes’ reaction
with T7-tagged immunoprecipitated proteins, UBE1, and ubiquitin. The proteins were analyzed by western blotting with anti-ZAP and anti-TRIM25
antibodies. c RNase A/T1 treatment substantially reduces efficiency of TRIM25-mediated ubiquitination of ZAP. Lane 1 shows immunoprecipitated T7-
TRIM25 and T7-ZAP. Lanes 2 and 3 represent control 60 minutes’ incubation of HeLa cell extracts in the absence and presence of RNases, respectively.
Lanes 4 and 7 show reactions with immunoprecipitated T7-ZAP, T7-TRIM25, 6xHis-Ube2D3, UBE1, and ubiquitin in the absence and presence of RNases,
respectively. Lanes 5 and 8 show reactions with immunoprecipitated T7-ZAP, T7-TRIM25, UBE1, and ubiquitin in the absence and presence of RNases,
respectively. Lanes 6 and 9 show reactions with immunoprecipitated T7-ZAP and T7-TRIM25 in the absence and presence of RNases, respectively. The
proteins were analyzed by western blotting with anti-ZAP and anti-TRIM25 antibodies. d Ubiquitination of T7-ZAP is mediated by T7-TRIM25. Control
incubation of immunoprecipitated T7-ZAP with 6xHis-Ube2D3, UBE1, and ubiquitin shows lack of ubiquitination. Lane 1 shows immunoprecipitated
T7-ZAP. Lanes 3–5 show incubation of T7-ZAP with 6xHis-Ube2D3, UBE1, and ubiquitin for 5, 30, and 60 minutes, respectively. The proteins were
analyzed by western blotting with anti-ZAP antibody
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shorter 3′-UTRs, which exhibit increased stability and
produce more proteins in part through the loss of
microRNA-mediated repression [30]. Additionally, the
shortening of 3′-UTRs is associated with proliferating T
cells but is not accompanied by a corresponding change
in protein levels [31]. For these reasons, regulation of
the lengths of the 3′-UTRs could allow for tight control
of the type and amount of TRIM25 that is associated
with specific mRNAs and the subsequent ubiquitination/
ISGylation of nascent peptides. This could be an import-
ant mechanism in the physiological and pathological
control of protein stability and function. Importantly,
TRIM25 also binds to the 5′-UTRs of mRNAs and
within coding regions. Thus, the RNA-related functions
of TRIM25 might not be limited to 3′-UTRs, which
could result in different functions depending on where
in the RNA the TRIM25 binds.
Previously, the CC domain of TRIM25 has been impli-
cated in binding to RNA [3]. TRIM25 deletion mutants
lacking the CC domain were unable to interact with
RNA in the UV immunoprecipitation and T4 poly-
nucleotide kinase assays [3]. In contrast, the mutant
lacking the PRY/SPRY domain still retained its RNA-
binding ability. Surprisingly, the results from the
proteome-wide analysis of RNA-binding domains in
HeLa cells (Fig. 1b) [19], as well as the results obtained
from the RNA pull-down (Fig. 1e), EMSA (Fig. 1a, c),
co-IP (Fig. 3), and RIP (Fig. 4f, g) assays, implicate the
PRY/SPRY domain as the point of contact with the
RNA. This discrepancy could arise from the fact that de-
letion of the CC domain from TRIM25 eliminates its
dimerization [15, 17, 18] and oligomerization [16] ability
(Fig. 2c). While it is not univocally confirmed that
TRIM25 needs to dimerize to bind RNA, such a
phenomenon is widespread across many RNA-binding
proteins [20, 21]. Additionally, the experiments pre-
sented by Kwon et al. [3] were performed in wild-type
mouse embryonic stem cells, where levels of endogenous
TRIM25 are particularly high. This means that any ec-
topically overexpressed TRIM25 mutant (if it has the CC
domain), including TRIM25ΔPRY/SPRY, will have a
chance to heterodimerize with the wild-type, endogen-
ous TRIM25, which could mask the requirements for a
TRIM25 domain, such as PRY/SPRY, to bind to RNA.
Our RNA pull-down data with the extracts from the
TRIM25 KO cells clearly demonstrated that T7-
TRIM25ΔPRY/SPRY could not bind RNA (Fig. 1g). Fur-
ther structural characterization of the TRIM25/RNA
complex should reveal detailed features of this inter-
action and shed more light on this novel, putative RNA-
binding domain.
Importantly, there are more than 80 TRIM proteins in
the human genome [5], divided into 11 subfamilies
based on their structural composition; 43 of these have
PRY/SPRY domains (subfamilies C-I and C-IV). Al-
though there is a high degree of similarity between them,
only TRIM25 (from TRIM proteins containing PRY/
SPRY) was identified in HeLa [1] and mouse embryonic
stem cell [3] screens for proteins that bind to RNAs,
which could reflect a lack of saturation of RNA-capture
screens or lack of expression of many other PRY/SPRY-
containing TRIM proteins in the cell lines used for these
assays. Interestingly, another protein from the TRIM
family, TRIM71, was shown to use its NHL, but not its
CC, domain to bind RNA [3, 32]. Our results from the
RNA pull-down experiments with chimeric TRIM25/
TRIM5, TRIM25/TRIM21, TRIM25/TRIM27, and
TRIM25/TRIM65 proteins indicate that other TRIM
proteins with the PRY/SPRY domain could harbor yet
undiscovered RNA-binding potential (Fig. 7). Thus, in
the future, it will be important to assay other TRIM pro-
teins to determine their RNA-binding activities. Notably,
other E3 ubiquitin ligases, including Mex3b and Dizip3,
have been shown to use RNA as a scaffold to mediate
the ubiquitination of their substrates, which are bound
to the same RNA [33]. Roquin is another example of an
E3 ubiquitin ligase with a well-established RNA-binding
ability [34]. Moreover, the BRACA1 E3 ubiquitin ligase,
which is implicated in familial breast cancer, has been
a
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Fig. 9 RNA is important for TRIM25’s E3 ubiquitin ligase function.
a Proposed model whereby ubiquitin ligase activity of TRIM25 is
substantially enhanced by using RNA as a scaffold. b Proposed model
whereby binding of TRIM25 to RNA could enhance its ubiquitin ligase
activity by allosteric change
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shown to interact with RNAs [35]. Altogether, these re-
sults strongly suggest the possibility of widespread roles
of E3 ubiquitin ligases in the direct regulation of RNA
metabolism.
TRIM25 is involved in normal development and dis-
ease [36]. For example, TRIM25 has been implicated in
estrogen-dependent organ development [37]. Conse-
quently, TRIM25 KO mice present significantly under-
developed uteri [38, 39]. Furthermore, TRIM25 plays a
role in promoting proliferation of many cancer cell
types, often in association with the estrogen response
[40–43]. Recently, TRIM25 has been shown to be a mas-
ter regulator of breast cancer metastasis [26]. Addition-
ally, TRIM25 is known for its role in the RIG-I-mediated
interferon pathway [5, 8]. Upon detection of viral RNAs
with 5′-ppp-RNA, RIG-I activates a signaling cascade
that results in phosphorylation-mediated dimerization of
the transcription factor IRF3, leading to type I interferon
(interferon α and β) expression [9, 10]. K63-linked ubi-
quitination of RIG-I by TRIM25 is required for an effi-
cient interferon response [11]. RIG-I can also be
stimulated by unanchored polyubiquitin chains gener-
ated by TRIM25 [44]. This interaction is targeted by vi-
ruses to suppress the interferon response. For example,
the influenza’s RNA-binding protein NS1 inhibits
TRIM25-mediated ubiquitination of RIG-I by binding to
the TRIM25 CC domain and disrupting its dimerization,
allowing the virus to avoid the innate immune response
[45]. This inhibitory activity is significantly reduced in
an NS1 mutant, R38A/K41A, which cannot bind RNA
[46], raising questions about a possible functional link
between the RNA-binding activities of TRIM25 and
NS1. Finally, the SARS-CoV nucleocapsid protein (N-
protein) has been shown to inhibit TRIM25 by binding
to TRIM25’s PRY/SPRY domain [47]. Considering our
results, it is plausible that N-protein could directly in-
hibit the TRIM25 RNA binding activity. To fully under-
stand the RNA-related role of TRIM25 in development
and disease, it will be important to characterize
TRIM25/RNA complexes, especially in the context of
RIG-I activation by viral RNAs.
Conclusions
In summary, we have presented the transcriptome and
proteome-wide interactomes of a novel RNA-binding
protein, TRIM25. We showed that the PRY/SPRY do-
main is responsible for the ability of TRIM25 to bind
RNA. Finally, we have provided evidence that RNA is an
important component in TRIM25’s ubiquitin ligase ac-
tivity. A recent genome-wide bioinformatics screen of
the human proteome identified more than 2600 proteins
with RNA-binding capacity [48]. Unravelling the RNA-
related characteristics and functions of these proteins,
including TRIM25, will undoubtedly reveal novel bio-
logically and medically relevant molecular pathways.
Methods
EMSA
EMSAs were performed with an end-labeled pre-let-7a-1
probe (50 × 103 counts per minute, ~0.1 pmol) and the
indicated amounts of proteins produced in E. coli. Bind-
ing reactions were performed in 16-μL reactions con-
taining gel exclusion buffer (4.8 mM Tris (pH 8),
144 mM NaCl, 0.96 mM DTT) supplemented with
3 mM MgCl2, 0.5 mM ATP, and 37.5 mM creatine phos-
phate. Reactions were incubated at 4 °C for 1 h, followed
by electrophoresis on a 6% w/v non-denaturing poly-
acrylamide gel. The signal was recorded with radio-
graphic film or as exposed to a phosphoimaging screen
and scanned on a FLA-5100 scanner (Fujifilm).
RNA pull-down assay
RNA pull-down assays were performed as previously de-
scribed [49], with slight modifications. Briefly, total pro-
tein extracts were incubated with in vitro-transcribed
RNAs that were chemically coupled to beads [50]. The
incubation was followed by a series of washes with buf-
fer G (20 mM Tris (pH 7.5), 135 mM NaCl, 1.5 mM
MgCl2, 10% v/v glycerol, 1 mM EDTA, 1 mM dithio-
threitol, and 0.2 mM phenylmethanesulfonyl fluoride).
After the final wash, the proteins associated with the
beads were analyzed by western blotting.
Co-immunoprecipitation
Extracts prepared from HeLa cells transfected with plas-
mids expressing T7-tagged or EGFP-tagged proteins
were incubated with protein A agarose with the anti-T7
antibody. The bound proteins were separated on a 4–
12% SDS polyacrylamide gel and analyzed by western
blotting. As indicated, some samples were treated with
RNases A and T1 prior to loading on the gel. For mass
spectrometry, the T7-bound beads were incubated with
HeLa extracts grown in Light or Heavy R6K4 (13C-la-
beled arginine and 2D-labeled lysine) isotopes (Dundee
Cell Products LM014/16). Next, the bound proteins
were run on a 4–12% SDS polyacrylamide gel followed
by in-gel digestion as described previously [49]. Gene
Ontology enrichment mapping was performed by func-
tionally annotating the enriched proteins using DAVID
[22] and visualizing them with the Enrichment Map Plu-
gin v2.1.0 [23] in Cytoscape (P value cutoff = 0.001; false
discovery rate Q-value cutoff = 0.1; Jaccard coefficient =
0.25). Enriched protein sets are represented as nodes
(red circles) connected by edges (green lines), with the
sizes of nodes and edges representing the number of
proteins in gene sets and the amount of overlap.
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CLIP-seq
The protocol was adapted from Moore et al. [51] using
adapters and PCR oligonucleotides described by Kilchert
et al. [52]. Briefly, two P100 dishes per sample were
transfected with plasmid expressing T7-tagged TRIM25.
Anti-T7 antibody was coupled to 50 μL of Dynabeads
per sample. Following immunoprecipitation, the RNA
was dephosphorylated, the 3′ linker was ligated and
radiolabeled, and the 5′ linker was ligated on the beads.
The 3′ linker reaction was performed in a total of 80 μL,
with 1× PNK buffer, 1 μM 3′ adapter (3′ adapter in
CLIP oligos), 800 U T4 RNA ligase 2 truncated K227Q,
80 U RNase out, and 10% PEG 8000. The 5′ linker reac-
tion occurred in a total of 80 μL, with 1× PNK buffer,
1 mM ATP, 12.5 nM 5′ linker L5B (L5Ba-d in CLIP oli-
gos), 80 U RNase OUT, and 40 U T4 RNA ligase. The
RNA was reverse transcribed (RT Oligo in CLIP oligos)
and amplified by PCR (P5_Forward and P3_barcode Re-
verse BC1 or BC2) using LA Takara Taq. The libraries
were analyzed on an Illumina Miseq system, and the
data were processed using the pyCRAC software [25].
TRIM25 binding motifs were analyzed using pyMotif
and WebLogo on identified clusters. The distribution of
TRIM25 CLIP clusters across the protein coding genes
was performed using pyBinCollector. The correlation be-
tween the experiments was calculated by comparing the
heights of the clusters in the three experiments. The
correlation with total RNA abundance was performed by
comparing the heights of the clusters common in all
three experiments with the transcript abundance in the
RNA-seq data derived from HeLa cells.
RIP
The RIP experiments were performed as in the CLIP-seq
immunoprecipitations, except for cross-linking and
RNase treatment. The bound RNAs were isolated by
Trizol extraction, and RNAs were identified by qRT-
PCR, using the SuperScript III Platinum SYBR Green
One-Step qRT–PCR Kit (Life Technologies) following
the manufacturer’s instructions on a Roche 480
LightCycler.
In vitro ubiquitination
Immunoprecipitation was performed as described above.
Following the final wash, proteins bound to beads were
incubated with Ube1, His-Ube2D3, and ubiquitin (UBP-
Bio), where 1 mg/mL of Ube1, 2 mg/mL of His-Ube2D3,
and 50 mg/mL of ubiquitin were used for TRIM25 auto-
ubiquitination and 5 mg/mL of Ube1, 10 mg/mL of His-
Ube2D3, and 250 mg/mL of ubiquitin were used for
ZAP ubiquitination. The reactions were carried out at
37 °C for 1 hour or as otherwise indicated and were
stopped by addition of loading buffer and reducing
agent. The protein ubiquitination was analyzed by west-
ern blot with anti-TRIM25 or anti-ZAP antibodies.
Western blot
Total protein samples were resolved by standard
NuPAGE SDS-PAGE electrophoresis with MOPS run-
ning buffer (Life Technologies) and transferred onto a
nitrocellulose membrane. The membrane was blocked
overnight at 4 °C with 1:10 western blocking reagent
(Roche) in Tris-buffered saline buffer with 0.1% Tween-
20 (TBST). The following day, the membrane was incu-
bated for 1 hour at room temperature with the primary
antibody solution in 1:20 western blocking reagent di-
luted in TBST. Antibodies used included rabbit poly-
clonal anti-TRIM25 (1:1000, ab167154, clone EPR7315,
Abcam), rabbit polyclonal anti-DHX9 (1:1000, 17721-1-
AP, RRID – AB_2092506, Protein-Tech), mouse mono-
clonal anti-tubulin (1:10000, T6199, RRID – AB_477583,
Sigma-Aldrich), mouse monoclonal anti-T7 tag HRP
conjugate (1:10000, 69048, RRID – AB10807495, Nova-
gen), mouse monoclonal anti-HA-probe HRP conjugate
(1:1000, sc-7392HRP, F-7, Santa Cruz), rabbit monoclo-
nal anti-DDX5 (1:1000, ab126730, RRID – AB_111
30291, Abcam), and rabbit polyclonal anti-ZAP
(ZC3HAV1) (1:1000, 16820-1-AP, Protein-Tech). After
washing in TBST, the blots were incubated with the ap-
propriate secondary antibody conjugated to horseradish
peroxidase and detected with the SuperSignal West Pico
detection reagent (Thermo Scientific) or WesternSure
ECL substrate (Licor). The membranes were stripped
using the ReBlot Plus Strong Antibody Stripping Solution
(Chemicon) equilibrated in water, blocked in 1:10 western
blocking solution in TBST, and re-probed as described
above.
Cell culture, overexpression, and actinomycin D treatment
HeLa cells (American Type Culture Collection) were
maintained in standard Dulbecco’s modified Eagle’s
medium (DMEM) (Life Technologies), supplemented
with 10% fetal bovine serum (Life Technologies). For
SILAC mass spectrometry, cells were cultured in DMEM
supplemented with Light or Heavy R6K4 (13C-labeled ar-
ginine and 2D-labeled lysine) isotopes (Dundee Cell
Products LM014/16). Fragments encoding proteins of
interest were cloned into the pCG T7 plasmid and tran-
siently expressed in HeLa cells using Lipofectamine
2000 (Invitrogen). For RNA stability assays, 10 μg/mL of
actinomycin D (Sigma) was added to cells and RNA ex-
tracted at the time points indicated using Tri Reagent
(Sigma). Levels of RNAs of interest were determined by
qRT-PCR using SuperScript III Platinum SYBR Green
One-Step qRT-PCR Kit (Thermo-Fisher). A total of
200 ng of RNA were loaded per well for RNAs of inter-
est and these levels were normalized to 18S Ribosomal
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RNA, for which 1 ng of total RNA was loaded per well
(1 in 200 dilution).
Recombinant protein purification
The full-length human TRIM25 and RBD mutant were
cloned into pET30a, which was transformed into BL21
gold cells. Bacteria was grown in Superbroth in the pres-
ence of kanamycin at 37 °C until the OD600 reached 0.6.
The bacteria were induced by 0.5 mM IPTG and incu-
bated for 24 hours at 30 °C with agitation. Pellets were
lysed with a cell disruptor in lysis buffer (20 mM NaPPi
(pH 7.4), 500 mM NaCl, 5 mM MgCl2, protease inhibi-
tor, DNase, and RNase or benzonase), and lysates were
loaded onto an IMAC HiTrap 1-mL FF column in bind-
ing buffer (20 mM NaPPi (pH 7.4), 500 mM NaCl,
10 mM imidazole) and eluted with increasing amounts
of elution buffer (20 mM NaPPi (pH 7.4), 500 mM NaCl,
500 mM imidazole). Protein fractions were further puri-
fied with a gel exclusion column (Superdex 200 30/100
GL or HiLoad Superdex 200 16/60) in gel exclusion buf-
fer (10 mM Tris (pH 8.0), 300 mM NaCl, 2 mM DTT).
Selected fractions were pooled and concentrated using
Vivaspin 5 30,000 MWCO (Sartorius Stedim UK Ltd.).
His-Lin28s was produced and purified as previously
specified [53].
Thermal denaturation assay
Thermal denaturation assays were performed on a Bio-
Rad IQ5 ICycler. Recombinant proteins (~4 μM) were
mixed with Sypro orange (×5) in a 50-μL reaction. Fluor-
escent readings were taken every 30 seconds between
20 °C and 70 °C. The melting temperature was deter-
mined from the maximum of the first derivative of the
melting curve, and the mean melting temperature of
three replicates was calculated for each protein.
Size exclusion chromatography with multi-angle light
scattering
Mass measurements were performed on a Viscotek
MALS-20 and VE3580 RI detector attached to an ÄKTA
10 Purifier with microflow components. Protein samples
were run at approximately 0.75 mg/mL on a Super-
dex200 Increase 10/300 GL column, running at 1.0 mL/
min in gel exclusion buffer (with 0.5 mM TCEP instead
of DTT) with 100-μL injections.
TRIM25 CRISPR/Cas9 knockout
HeLa cells were transfected with 200 ng of GeneArt
CRISPR Nuclease mRNA (Thermo-Fisher) in addition to
50 ng of each of two sgRNAs (TRIM25 Left sgRNA –
CCACGTTGCACAGCACCGTGTTC and TRIM25 Right
sgRNA CTGCGGTCGCGCCTGGTAGACGG) targeting
sequences in exon 1 of TRIM25. After 24 hours, cells were
seeded to a 96-well plate such that there was on average 1
cell per well, and the cells were grown until colonies were
visible to the naked eye. Next, cells were split into two 96-
well plates, one of which was used for a dot blot analysis.
For the dot blot analysis, cells were washed twice in PBS
prior to the addition of 30 μL of Passive Lysis Buffer (Pro-
mega) per well and incubation for 15 minutes at room
temperature. Two microliters of protein from each well
was spotted directly onto a nitrocellulose membrane,
followed by western blotting, as described above. Selected
clones were seeded from the second 96-well plate into 6-
well plates, grown, and TRIM25 levels were validated by
standard western blotting.
CLIP oligonucleotides
L5Ba: 5′-invddT-ACACrGrArCrGrCrUrCrUrUrCrCrGrA
rUrCrUrNrNrNrArGrArGrCrN-OH-3′. L5Bb: 5′-invddT-
ACACrGrArCrGrCrUrCrUrUrCrCrGrArUrCrUrNrNrNr
GrUrGrArGrCrN-OH-3′. L5Bc: 5′-invddT-ACACrGrArC
rGrCrUrCrUrUrCrCrGrArUrCrUrNrNrNrCrArCrUrArG
rCrN-OH-3′. L5Bd: 5′-invddT-ACACrGrArCrGrCrUr
CrUrUrCrCrGrArUrCrUrNrNrNrUrCrUrCrUrArGrCrN-
OH-3′. 3′ adapter: 5′App-NAGATCGGAAGAGCACAC
GTCTG-ddC 3′. RT Oligo: 5′-CAGACGTGTGCTCTTC
CGATCT-3′.
PCR oligonucleotides
P5_Forward: 5′-AATGATACGGCGACCACCGAGATC
TACACTCTTTCCCTACACGACGCTCTTCCGATCT-
3′. P3_barcode_Reverse: BC1: 5′CAAGCAGAAGACG
GCATACGAGATCGTGATGTGACTGGAGTTCAGAC
GTGTGCTCTTCCGATCT-3′ (has indexing barcode
IDX1). BC2: 5′CAAGCAGAAGACGGCATACGAGATA
CATCGGTGACTGGAGTTCAGACGTGTGCTCTTCC
GATCT-3′ (has indexing barcode IDX2).
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